Dimed Distribuidora de Medicamentos Future Growth

Future criteria checks 4/6

Dimed Distribuidora de Medicamentos is forecast to grow earnings and revenue by 43.3% and 12.4% per annum respectively. EPS is expected to grow by 54.9% per annum. Return on equity is forecast to be 16.7% in 3 years.

Key information

43.3%

Earnings growth rate

54.9%

EPS growth rate

Consumer Retailing earnings growth	31.0%
Revenue growth rate	12.4%
Future return on equity	16.7%
Analyst coverage	Low
Last updated	20 Apr 2024

Recent future growth updates

Recent updates

Investors Could Be Concerned With Dimed Distribuidora de Medicamentos' (BVMF:PNVL3) Returns On Capital

Nov 04

These 4 Measures Indicate That Dimed Distribuidora de Medicamentos (BVMF:PNVL3) Is Using Debt Extensively

Jul 12

Investors Shouldn't Be Too Comfortable With Dimed Distribuidora de Medicamentos' (BVMF:PNVL3) Robust Earnings

May 27

Be Wary Of Dimed Distribuidora de Medicamentos (BVMF:PNVL3) And Its Returns On Capital

Apr 15

Dimed Distribuidora de Medicamentos (BVMF:PNVL3) Seems To Use Debt Quite Sensibly

Mar 25

The Returns On Capital At Dimed Distribuidora de Medicamentos (BVMF:PNVL3) Don't Inspire Confidence

Jan 06

Dimed S.A. Distribuidora de Medicamentos' (BVMF:PNVL3) Stock Retreats 26% But Earnings Haven't Escaped The Attention Of Investors

Oct 23

Dimed Distribuidora de Medicamentos (BVMF:PNVL3) Is Reinvesting At Lower Rates Of Return

Aug 15

Earnings and Revenue Growth Forecasts

BOVESPA:PNVL3 - Analysts future estimates and past financials data (BRL Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2026	6,490	404	N/A	N/A	2
12/31/2025	5,765	314	N/A	401	2
12/31/2024	5,083	173	N/A	347	2
12/31/2023	4,461	93	157	297	N/A
9/30/2023	4,325	88	144	282	N/A
6/30/2023	4,211	83	175	325	N/A
3/31/2023	4,116	84	69	228	N/A
12/31/2022	3,990	86	24	205	N/A
9/30/2022	3,799	85	17	198	N/A
6/30/2022	3,584	83	21	189	N/A
3/31/2022	3,375	80	15	175	N/A
12/31/2021	3,225	79	-4	131	N/A
9/30/2021	3,135	79	-56	78	N/A
6/30/2021	3,032	79	-58	63	N/A
3/31/2021	2,878	62	-41	57	N/A
12/31/2020	2,819	56	46	131	N/A
9/30/2020	2,764	56	82	147	N/A
6/30/2020	2,754	62	34	90	N/A
3/31/2020	2,780	78	73	133	N/A
12/31/2019	2,725	77	75	129	N/A
9/30/2019	2,638	80	89	131	N/A
6/30/2019	2,562	79	65	106	N/A
3/31/2019	2,500	76	72	117	N/A
12/31/2018	2,432	75	51	110	N/A
9/30/2018	2,359	65	-20	45	N/A
6/30/2018	2,317	59	-1	62	N/A
3/31/2018	2,282	59	-27	29	N/A
12/31/2017	2,258	60	-2	41	N/A
9/30/2017	2,238	60	N/A	78	N/A
6/30/2017	2,191	59	N/A	68	N/A
3/31/2017	2,146	57	N/A	104	N/A
12/31/2016	2,129	53	N/A	102	N/A
9/30/2016	2,095	53	N/A	92	N/A
6/30/2016	2,074	50	N/A	93	N/A
3/31/2016	2,043	50	N/A	76	N/A
12/31/2015	1,986	45	N/A	73	N/A
9/30/2015	1,963	44	N/A	59	N/A
6/30/2015	1,927	43	N/A	56	N/A
3/31/2015	1,916	48	N/A	26	N/A
12/31/2014	1,887	49	N/A	23	N/A
9/30/2014	1,835	50	N/A	29	N/A
6/30/2014	1,823	58	N/A	50	N/A
3/31/2014	1,786	55	N/A	66	N/A
12/31/2013	1,740	56	N/A	62	N/A
9/30/2013	1,687	54	N/A	46	N/A
6/30/2013	1,619	49	N/A	27	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: PNVL3's forecast earnings growth (43.3% per year) is above the savings rate (9.9%).

Earnings vs Market: PNVL3's earnings (43.3% per year) are forecast to grow faster than the BR market (13.9% per year).

High Growth Earnings: PNVL3's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: PNVL3's revenue (12.4% per year) is forecast to grow faster than the BR market (7.2% per year).

High Growth Revenue: PNVL3's revenue (12.4% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: PNVL3's Return on Equity is forecast to be low in 3 years time (16.7%).

Dimed Distribuidora de Medicamentos Future Growth

Future criteria checks 4/6

Key information

Recent future growth updates

Price target decreased by 8.8% to R$17.65

Price target decreased by 9.1% to R$18.72

Price target decreased to R$22.85

Price target decreased to R$30.20

Recent updates

Full year 2023 earnings: Revenues in line with analyst expectations

Upcoming dividend of R$0.068 per share at 1.9% yield

Third quarter 2023 earnings released: EPS: R$0.16 (vs R$0.12 in 3Q 2022)

Upcoming dividend of R$0.046 per share at 1.6% yield

Second quarter 2023 earnings released: EPS: R$0.15 (vs R$0.16 in 2Q 2022)

Price target decreased by 8.8% to R$17.65

Price target decreased by 9.1% to R$18.72

Full year 2022 earnings released: EPS: R$0.58 (vs R$0.53 in FY 2021)

No independent directors

Third quarter 2022 earnings released

Investor sentiment deteriorated over the past week

Investors Could Be Concerned With Dimed Distribuidora de Medicamentos' (BVMF:PNVL3) Returns On Capital

Second quarter 2022 earnings released

These 4 Measures Indicate That Dimed Distribuidora de Medicamentos (BVMF:PNVL3) Is Using Debt Extensively

Investors Shouldn't Be Too Comfortable With Dimed Distribuidora de Medicamentos' (BVMF:PNVL3) Robust Earnings

First quarter 2022 earnings: Revenues exceed analyst expectations

Price target decreased to R$22.85

No independent directors

Be Wary Of Dimed Distribuidora de Medicamentos (BVMF:PNVL3) And Its Returns On Capital

Full year 2021 earnings: EPS misses analyst expectations

Dimed Distribuidora de Medicamentos (BVMF:PNVL3) Seems To Use Debt Quite Sensibly

Investor sentiment deteriorated over the past week

The Returns On Capital At Dimed Distribuidora de Medicamentos (BVMF:PNVL3) Don't Inspire Confidence

Price target decreased to R$30.20

Third quarter 2021 earnings released

Dimed S.A. Distribuidora de Medicamentos' (BVMF:PNVL3) Stock Retreats 26% But Earnings Haven't Escaped The Attention Of Investors

Investor sentiment deteriorated over the past week

Upcoming dividend of R$0.034 per share

Dimed Distribuidora de Medicamentos (BVMF:PNVL3) Is Reinvesting At Lower Rates Of Return

Dimed S.A. Distribuidora de Medicamentos(BOVESPA:PNVL4) dropped from Brazil Special Tag Along Stock Index

Dimed S.A. Distribuidora de Medicamentos announced that it expects to receive funding from Kinea Private Equity Investimentos S.A.

Dimed S.A. Distribuidora de Medicamentos has completed a Follow-on Equity Offering in the amount of BRL 1.036713 billion.

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings per Share Growth Forecasts

Future Return on Equity

Discover growth companies